Source: Clinical Infectious Diseases. Unidade: FMRP
Subjects: ANTI-HIV (ADMINISTRAÇÃO E DOSAGEM), INFECÇÕES POR HIV (QUIMIOTERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NACHMAN, Sharon et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years. Clinical Infectious Diseases, v. 58, n. 3, p. 413-422, 2014Tradução . . Disponível em: https://doi.org/10.1093/cid/cit696. Acesso em: 03 maio 2024.APA
Nachman, S., Zheng, N., Acosta, E. P., Teppler, H., Homony, B., Graham, B., et al. (2014). Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years. Clinical Infectious Diseases, 58( 3), 413-422. doi:10.1093/cid/cit696NLM
Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A, Cervi MC. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years [Internet]. Clinical Infectious Diseases. 2014 ; 58( 3): 413-422.[citado 2024 maio 03 ] Available from: https://doi.org/10.1093/cid/cit696Vancouver
Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A, Cervi MC. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years [Internet]. Clinical Infectious Diseases. 2014 ; 58( 3): 413-422.[citado 2024 maio 03 ] Available from: https://doi.org/10.1093/cid/cit696